Key facts
- Autobahn Therapeutics’s last known valuation is $218.0M.
- It has raised $214.5M across 1 recorded rounds; the latest was Later Stage VC ($100.8M) in Jun 2024.
- Notable investors include Insight Partners (New York), Alexandria Venture Investments, Canaan Partners, ARCH Venture Partners, Blue Owl Capital — 18 tracked in total.
- Autobahn Therapeutics has filed 1 Form D with the SEC, most recently Aug 2024 ($100.8M sold to 22 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Autobahn Therapeutics
Funding rounds
1 roundsAbout Autobahn Therapeutics
Developer of regenerative medicines and brain-targeting therapeutics intended for restoring the hopes of people affected by central nervous system disorders. The company's medicines are focused on high unmet need areas of neuropsychiatry, neurodegeneration and neuroinflammation with aims to unlock new therapeutic opportunities through precision tuning of CNS(Central nervous system) exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers, enabling patients with major depressive disorder and bipolar disorder depression to live the futures they deserve.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2017
- Employees
- 32
- Website
- autobahntx.com/
- Ownership
- Privately Held (backing)
Autobahn Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Autobahn Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Autobahn Therapeutics in its N-PORT filings yet. We sweep new filings monthly.